Prophylactic Ketorolac Post Epiretinal Membrane Surgery

Queen's University18 enrolled

Overview

Evaluate the efficacy of ketorolac 0.5%, a topical non-steroidal anti-inflammatory drug (NSAID), to prevent macular edema after epiretinal membrane surgery. Patients undergoing epiretinal membrane surgery have increased risk of macular swelling which can adversely affect vision. Since post-intraocular surgery inflammation is a contributing factor to macular swelling and loss of vision, NSAID drops may be able to prevent or minimize the deleterious effects of macular swelling after epiretinal membrane surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

Conditions

Macular Edema

Interventions

Ketorolac 0.5%DRUG

Four-times a day starting one week before surgery and continued for 4 weeks post surgery.

Saline dropsOTHER

Four-times a day starting one week before surgery and continued for 4 weeks post surgery.

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * idiopathic epiretinal membrane diagnosis requiring membrane peel surgery Exclusion Criteria: * proliferative diabetic retinopathy * sickle cell retinopathy * radiation retinopathy * choroidal folds * hypersensitivity or allergy to NSAIDs * wet macular degeneration * branch retinal vein occlusion (BRVO) * central retinal vein occlusion (CRVO) * complicated membrane peel surgery

Locations (1)

Department of Ophthalmology, Hotel Dieu Hospital, Queen's University

Kingston, Ontario, Canada

Outcomes

Primary Outcomes

Change in macular volume from baseline.

Time frame: Before surgery, at 1 week, 1 month, and 1 year after surgery.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.